<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234038</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 183750-CS4</org_study_id>
    <nct_id>NCT01234038</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>A Phase 1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the overall survival of patients with Stage IV&#xD;
      non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin&#xD;
      and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At the end of each 21 day cycle</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle</description>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients age &gt;/= 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of NSCLC&#xD;
&#xD;
          -  Stage IV disease (including patients with pleural effusion who were previously&#xD;
             classified as Stage IIIB)&#xD;
&#xD;
          -  All of the following if patient has had prior radiation therapy:&#xD;
&#xD;
               1. Lesion(s) used for determination of response were not previously irradiated or&#xD;
                  have increased in size since the completion of radiotherapy&#xD;
&#xD;
               2. The patient has recovered from any acute effects of the radiotherapy&#xD;
&#xD;
               3. Radiotherapy was completed at least 4 weeks prior to Screening&#xD;
&#xD;
          -  Part 1: Have at least non-measurable evaluable disease (e.g., lesions which are&#xD;
             smaller than the minimum size required for measurability; other non-measurable lesions&#xD;
             such as bone metastases, malignant pleural effusion)&#xD;
&#xD;
          -  Part 2: Have measurable disease, defined as at least 1 lesion that can be accurately&#xD;
             measured in at least 1 dimension&#xD;
&#xD;
          -  Performance status of 0 or 1 on the ECOG Performance Status Scale&#xD;
&#xD;
          -  Have an estimated life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate organ function within 14 days prior to first study dose (ISIS EIF4E Rx or&#xD;
             carboplatin/paclitaxel, whichever occurs first) as defined by:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &gt;/= 1.5 x 109/L&#xD;
&#xD;
               2. Platelet count &gt;/= 100 x 109/L&#xD;
&#xD;
               3. Hemoglobin &gt;/=9 g/dL (&gt;/= 5.6 mmol/L). Patients may receive packed RBC&#xD;
                  transfusion to achieve this level at the discretion of the investigator.&#xD;
&#xD;
               4. Total bilirubin &lt; 1.5 x upper limit of normal (ULN) unless elevated secondary to&#xD;
                  conditions such as Gilbert's Disease&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) &lt; 3 x ULN (&lt; 5 x ULN in the presence of hepatic&#xD;
                  metastases)&#xD;
&#xD;
               6. Alanine aminotransferase (ALT) &lt; 3 x ULN (&lt; 5 x ULN in the presence of hepatic&#xD;
                  metastases)&#xD;
&#xD;
               7. Alkaline phosphatase &lt; 3.0 x ULN&#xD;
&#xD;
               8. Calculated creatinine clearance &gt;/= 60 mL/min per Cockcroft and Gault formula&#xD;
&#xD;
          -  Satisfy one of the following:&#xD;
&#xD;
               1. Females: non-pregnant and non-lactating; surgically sterile, post-menopausal, or&#xD;
                  patient or partner compliant with a reliable contraceptive regimen, as determined&#xD;
                  by Investigator, for 4 weeks prior to Screening. Patients of reproductive&#xD;
                  potential must test negative for pregnancy at Screen and must agree to use a&#xD;
                  reliable method of birth control during the study and for the 10 weeks following&#xD;
                  the last dose of ISIS EIF4E Rx.&#xD;
&#xD;
               2. Males: surgically sterile or patient or partner must agree to use a reliable&#xD;
                  contraceptive method, as determined by the Investigator during the study and for&#xD;
                  the 10 weeks following the last dose of ISIS EIF4E Rx.&#xD;
&#xD;
          -  For Part 1: have discontinued all prior chemotherapies, biological therapies, and&#xD;
             other investigational therapies for cancer for at least 4 weeks (6 weeks for&#xD;
             mitomycin-C or nitrosoureas) prior to study treatment and recovered from the acute&#xD;
             effects of therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part 1: More than 2 prior chemotherapy or biological therapy regimens (approved or&#xD;
             experimental) for NSCLC, not counting adjuvant and neoadjuvant treatment. A regimen is&#xD;
             defined as two or more consecutive cycles of treatment.&#xD;
&#xD;
          -  Part 2: Any prior chemotherapy or biological therapy (approved or experimental) for&#xD;
             NSCLC including adjuvant and neoadjuvant treatments&#xD;
&#xD;
          -  Treatment with another investigational drug, biological agent, or device within 4&#xD;
             weeks (6 weeks for biological agents) before Screening or 5 half-lives of study agent,&#xD;
             whichever is longer&#xD;
&#xD;
          -  Patients with treated or untreated parenchymal brain metastases or leptomeningeal&#xD;
             disease. Brain imaging is required for symptomatic patients to rule out brain&#xD;
             metastases, but is not required in asymptomatic patients.&#xD;
&#xD;
          -  Patients with known pericardial effusion&#xD;
&#xD;
          -  Have active infection or serious concomitant systemic disorder (for example, heart&#xD;
             failure) incompatible with the study (at the discretion of the Investigator)&#xD;
&#xD;
          -  Presence or history of malignancy other than NSCLC, carcinoma in situ of the cervix,&#xD;
             or non-melanoma skin cancer. In the case of other malignancies, patients may be&#xD;
             considered for participation if the prior malignancies were diagnosed and definitively&#xD;
             treated at least five years previously with no subsequent evidence of recurrence.&#xD;
&#xD;
          -  Presence of an underlying disease state associated with active bleeding&#xD;
&#xD;
          -  Ongoing therapy with oral or parenteral anticoagulants (e.g., heparin,&#xD;
             warfarin/coumadin). Low-dose anticoagulants for maintenance of catheter patency and&#xD;
             low dose aspirin (≤ 325 mg/day) and nonsteroidal anti-inflammatory agents are not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Concurrent treatment with other anticancer drugs&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy &gt;/=Common Terminology Criteria for Adverse Events&#xD;
             Version 4.0 (CTCAE) Grade 2&#xD;
&#xD;
          -  Known history of HIV, HCV, or chronic HBV infection&#xD;
&#xD;
          -  Previous treatment with a therapeutic antisense oligonucleotide or siRNA&#xD;
&#xD;
          -  Planned concomitant participation in another clinical trial of an experimental agent,&#xD;
             vaccine, or device&#xD;
&#xD;
          -  Have any other medical conditions that in the opinion of the Investigator, would make&#xD;
             the patient unsuitable for enrollment, or could interfere with the patient&#xD;
             participating in or completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Cancer Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenmar Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Hematology Oncology Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville - James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital &amp; St. Mary's Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Thoracic Diseases of Csongrad County Local Governmental</name>
      <address>
        <city>Deszk</city>
        <zip>H-6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Country Pandy Kalman Hospital</name>
      <address>
        <city>Gyula</city>
        <zip>H-5703</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Dluski Provincial Specialist Hospital</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No. 4 In Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idependent Public Tuberculosis an Lung Diseases Facilities</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Tuberculosis and Lung Diseases Hospitals</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-241</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alojzy Pawelec Provincial Hospital of Lung Diseases</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <zip>44-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Chemotherapy department</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Clinical Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution: Sverdlovsk Regional Oncology Center, Radiotherapy Department</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Ivanovo Regional Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Ivanovo</city>
        <zip>153013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Medical Institution: Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC Russian Railways, Chemotherapy Dept.</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Leningrad Regional Clinical Hospital, Thoracic Surgery Department</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution: &quot;City Clinical Oncology Center&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: St. Petersburg State Medica University n.a.I.P. Pavlov under the Federal Agency for Healthcare and Social Development, Pulmonology Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution: Samara Regional Clinical Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <disposition_first_submitted>June 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 27, 2018</disposition_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

